These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. [Cardiovascular risks of Cox-2-antagonists. Opinion on the marketed name rofecoxib, and its market-withdrawn valdecoxib and the actual therapeutic restrictions]. Bolten WW; Reiter S; Z Rheumatol; 2005 May; 64(4):286-9. PubMed ID: 15909092 [No Abstract] [Full Text] [Related]
10. Cardiovascular safety of the cyclooxygenase-2 selective inhibitors parecoxib and valdecoxib in the postoperative setting: an analysis of integrated data. Schug SA; Joshi GP; Camu F; Pan S; Cheung R Anesth Analg; 2009 Jan; 108(1):299-307. PubMed ID: 19095866 [TBL] [Abstract][Full Text] [Related]
11. New warnings for Bextra. FDA Consum; 2003; 37(1):5. PubMed ID: 12625292 [No Abstract] [Full Text] [Related]
12. A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years. Goldstein JL; Aisenberg J; Lanza F; Schwartz H; Sands GH; Berger MF; Pan S Clin Ther; 2006 Mar; 28(3):340-51. PubMed ID: 16750449 [TBL] [Abstract][Full Text] [Related]
13. Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization. Sun SX; Lee KY; Bertram CT; Goldstein JL Curr Med Res Opin; 2007 Aug; 23(8):1859-66. PubMed ID: 17605893 [TBL] [Abstract][Full Text] [Related]
14. Successful treatment of cystoid macular edema with valdecoxib. Reis A; Birnbaum F; Hansen LL; Reinhard T J Cataract Refract Surg; 2007 Apr; 33(4):682-5. PubMed ID: 17397743 [TBL] [Abstract][Full Text] [Related]